We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 303

Deference, Discovery and District Court Findings
  • McDermott Will & Emery
  • USA
  • March 28 2018

Giving deference on discovery issues and non-infringement findings, the US Court of Appeals for the Federal Circuit affirmed a non-infringement


New DOJ Task Force to Take on Opioid Crisis Using the FCA and Other Enforcement Tools
  • McDermott Will & Emery
  • USA
  • March 2 2018

Earlier this week, the US Department of Justice (DOJ) launched a new front in its effort to combat the opioid crisis and explicitly stated that it


On the Digital Health Frontier: Developments Driving Industry Change in 2018
  • McDermott Will & Emery
  • USA
  • January 25 2018

As digital health innovation continues to move at light speed, both new and incumbent stakeholders find themselves on a new


No State Law Remedies for Failure to Comply with BPCIA Notice
  • McDermott Will & Emery
  • USA
  • January 25 2018

On remand from the Supreme Court of the United States, the US Court of Appeals for the Federal Circuit held that under the Biologics Price


FDA 2017 Year in Review
  • McDermott Will & Emery
  • USA
  • January 11 2018

The US Food and Drug Administration's (FDA's) 2017 regulatory agenda was marked by inactivity in the months following the presidential inauguration


Totality of Evidence Must Be Considered in Assessing Obviousness
  • McDermott Will & Emery
  • USA
  • December 29 2017

The US Court of Appeals for the Federal Circuit reversed a finding of non-obviousness, concluding that the district court clearly erred in relying on


Antitrust Remains in Political Crosshairs for 2018 Midterm Elections
  • McDermott Will & Emery
  • USA
  • December 14 2017

Senator Elizabeth Warren (D-MA) gave a speech at the Open Markets Institute on December 6 entitled “Three Ways to Remake the American


McDermott's Reverse Engineered Podcast Five Hot FDA Issues for Life Science Companies
  • McDermott Will & Emery
  • USA
  • November 30 2017

Health-related technology is growing at an accelerating rate, as is its demand. The Food and Drug Administration (FDA), as the gatekeeper


FDA Publishes Supplemental Guidance on Menu Labeling for Chain Restaurants
  • McDermott Will & Emery
  • USA
  • November 20 2017

On November 7, the US Food and Drug Administration (FDA) published the latest in a series of industry draft guidance documents to help implement menu


Anticipated Acts of Infringement May Establish Venue for Hatch-Waxman
  • McDermott Will & Emery
  • USA
  • October 31 2017

Addressing venue in the context of Hatch-Waxman litigation, the US District Court for the District of Delaware held that venue is proper in Delaware